Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 2, 2021- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon-
Jul 29, 2021- Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic- Jot Dx™ ICM connects via Bluetooth with Abbott’s myMerlin™ mobile app for continuous remote monitoring, leading to a faster time to diagnosis compared to ICMs that may use traditional bedside monitors1- Abbott’s personalized concierge service, SyncUp™, provides one-on-one device setup support, helping patients connect Jot Dx™ ICM with the mobile app at home, taking the burden off physicians and clinic staff
Jul 29, 2021- Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss- Abbott's line of nutrition products scientifically designed for people with diabetes now includes Glucerna® 30g protein shakes to help people with diabetes meet important daily protein consumption goals- Jul 22, 2021- Sales growth of 39.5 percent; organic sales growth of 35.0 percent- GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent- Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019- Achieved strong sales growth across all four major business areas- Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
- Jun 30, 2021- New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)- The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants